[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366399-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366399-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","development-and-validation-of-g2m-signature-based-prognostic-model-for-stratifying-colon-cancer-prognosis","Development and validation of G2M signature-based prognostic model for stratifying colon cancer prognosis","","Background We aimed to develop a predictive model integrating G2M-related genes to enhance prognostication of colon cancer. Methods Using TCGA-COAD and GEO datasets (GSE39582, GSE17536, GSE17537), Cox regression with LASSO was applied to build a prognostic model and construct a nomogram for survival prediction. Results Univariate analysis yielded 15 genes, refined to nine hub genes. Multi-omics analysis assessed protein, miRNA, interactions, genomic variation, and drug sensitivity, enabling risk stratification and immune infiltration association. Conclusions The study presents a G2M-centered prognostic framework and an actionable nomogram.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/development-and-validation-of-g2m-signature-based-prognostic-model-for-stratifying-colon-cancer-prognosis/366399/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/development-and-validation-of-g2m-signature-based-prognostic-model-for-stratifying-colon-cancer-prognosis/366399.png","ImageObject",300,407,{"name":42,"@type":43},"Dipper","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of the G2M signature-based prognostic model for colon cancer?","Question",{"text":63,"@type":64},"To predict colon cancer outcomes by integrating G2M-related genes and improving clinical prognostication through risk stratification.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which datasets and statistical methods were used to develop the model?",{"text":68,"@type":64},"The model was developed using TCGA-COAD and GEO datasets (GSE39582, GSE17536, GSE17537) with Cox regression and LASSO, and a nomogram was created for survival prediction.",{"name":70,"@type":61,"acceptedAnswer":71},"How were the key prognostic genes selected in the study?",{"text":72,"@type":64},"Univariate Cox regression identified 15 common prognostic genes, and LASSO modeling refined them to nine hub genes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366399,1790929601,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Song et al. Discover Oncology (2025) 16:1516 [https://doi.org/10.1007/s12672-025-03355-9](https://doi.org/10.1007/s12672-025-03355-9)  \nDiscover Oncology  \nANALYSIS Open Access  \nDevelopment and validation of G2M signature- based prognostic model for stratifying colon cancer prognosis  \nXin Song 1, Yan Dou 1 and Xiaoyong Shen 1*  \n*Correspondence:  \nXiaoyong Shen [shenxiaoyong@tmu.edu.cn](shenxiaoyong@tmu.edu.cn)[ ](shenxiaoyong@tmu.edu.cn)1National Demonstration Center for Experimental Basic Medicine Education, School of Basic Medical Sciences, Tianjin Medical University, Qixiangtai Road No. 22, Heping District, Tianjin 300070, China  \nAbstract  \nBackground We aimed to develop a predictive model integrating G2M-related genes to enhance the prognostication of colon cancer.  \nMethods Based on the data from TCGA-COAD and GEO (GSE39582, GSE17536, GSE17537), we applied Cox regression with LASSO to create a colon cancer prognostic model and developed a Nomogram for survival prediction.  \nResults Our initial univariate Cox regression analysis identified 15 common prognostic genes. Subsequent LASSO modeling refined this set to nine hub genes: BRIP1, CDCA2, HMGCR, HOXC10, PSMA5, PSMD6, SIX4, SLC12A2, and SPA17 . Multi-omics analysis explored their protein expression, miRNA regulation, protein interactions, genomic variations, and drug sensitivity. The G2M prognostic model effectively categorized colon cancer patients into high-and low-risk groups, with the high-risk group showing significantly poorer overall survival. Further analysis of gene expression variances showed enrichment of extracellular matrix-related events. The G2M-based risk stratification correlated with the infiltration levels of immune cells, including Tregs, CD56dim natural killer cells, and M0-type macrophages. To aid clinical decision-making, we developed a Nomogram that developed the risk score with clinical parameters like tumor stage, age, and gender to forecast 1-, 3-, and 5-year survival rates.  \nConclusions This study presents an innovative prognostic model centered on the G2M, highlighting the indispensable role of G2M-related genes in colon cancer’s clinical progression.  \nKeywords Colon cancer, G2M, Prognosis, TCGA, GEO  \n1 Introduction  \nColon cancer, a prevalent malignancy of the colonic epithelium, is modulated by interconnected determinants including gut microbiome, bile acid metabolism, and immune surveillance mechanisms [1–3]. Robust prognostic model development remains critical for clinical risk stratification of colon cancer. Models like the one anchored in eight autophagy-related genes [4] and the other based on six stem cell-associated genes [5] have been developed to predict the potential progression of the disease.  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by-nc-nd/4.0/.  \nSong et al. Discover Oncology (2025) 16:1516 Page 2 of 18  \nCrucially, neoplastic progression is governed by dysregulation of the cell cycle—a process partitioned into G1 (","cbCaipvcftg6YEOf","https://ap.wps.com/l/cbCaipvcftg6YEOf","pdf",2979949,18,"English","# Abstract\n# Introduction\n# Materials and methods\n## G2M-related gene matrix and clinical parameters","[{\"question\":\"What is the purpose of the G2M signature-based prognostic model for colon cancer?\",\"answer\":\"To predict colon cancer outcomes by integrating G2M-related genes and improving clinical prognostication through risk stratification.\"},{\"question\":\"Which datasets and statistical methods were used to develop the model?\",\"answer\":\"The model was developed using TCGA-COAD and GEO datasets (GSE39582, GSE17536, GSE17537) with Cox regression and LASSO, and a nomogram was created for survival prediction.\"},{\"question\":\"How were the key prognostic genes selected in the study?\",\"answer\":\"Univariate Cox regression identified 15 common prognostic genes, and LASSO modeling refined them to nine hub genes.\"}]","Development and validation of G2M signature-based prognostic model for stratifying colon cancer prognosis | PDF",1790165297,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3ea213d4c6d38c40e27484581e84efb.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/588ebcc5ab4bc89d00da5dd68e7fba1e.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2701111d7b4d0ae6442b51f28fdabb27.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8fddc6ae9ab53ce75b042b0bad4ad807.webp",980,1306]